<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OPP</journal-id>
<journal-id journal-id-type="hwp">spopp</journal-id>
<journal-id journal-id-type="nlm-ta">J Oncol Pharm Pract</journal-id>
<journal-title>Journal of Oncology Pharmacy Practice</journal-title>
<issn pub-type="ppub">1078-1552</issn>
<issn pub-type="epub">1477-092X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1078155212438112</article-id>
<article-id pub-id-type="publisher-id">10.1177_1078155212438112</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Recurrent bone marrow aplasia secondary to nilotinib in a patient with chronic myeloid leukemia: A case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Prodduturi</surname><given-names>Prathima</given-names></name>
</contrib>
<aff id="aff1-1078155212438112">Department of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Perry</surname><given-names>Anamarija M</given-names></name>
</contrib>
<aff id="aff2-1078155212438112">Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Aoun</surname><given-names>Patricia</given-names></name>
</contrib>
<aff id="aff3-1078155212438112">Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Weisenburger</surname><given-names>Dennis D</given-names></name>
</contrib>
<aff id="aff4-1078155212438112">Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Akhtari</surname><given-names>Mojtaba</given-names></name>
<xref ref-type="corresp" rid="corresp1-1078155212438112"/>
</contrib>
</contrib-group>
<aff id="aff5-1078155212438112">Department of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE, USA</aff>
<author-notes>
<corresp id="corresp1-1078155212438112">Mojtaba Akhtari, Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198-7680, USA. Email: <email>mojtaba.akhtari@unmc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>4</issue>
<fpage>440</fpage>
<lpage>444</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Nilotinib is a potent tyrosine kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL), which has been approved as front-line therapy for newly diagnosed chronic myeloid leukemia in chronic phase and as second-line therapy after imatinib failure in chronic or accelerated phase chronic myeloid leukemia. Tyrosine kinase inhibitors have been associated with myelosuppression and grade 3 or grade 4 cytopenias are not uncommon in chronic myeloid leukemia patients treated with these drugs. There are a few reports of imatinib-associated bone marrow aplasia, but to our knowledge only one reported case of bone marrow aplasia associated with nilotinib. Herein, we report a 49-year-old male patient with chronic phase chronic myeloid leukemia, who developed severe bone marrow aplasia due to nilotinib. Possible mechanisms for this significant adverse drug reaction are discussed along with a review of literature.</p>
</abstract>
<kwd-group>
<kwd>Bone marrow aplasia</kwd>
<kwd>chronic myeloid leukemia</kwd>
<kwd>nilotinib</kwd>
<kwd>pancytopenia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1078155212438112" sec-type="intro"><title>Introduction</title>
<p>Nilotinib (Tasigna, formerly AMN107) is a selective tyrosine kinase inhibitor (TKI) of breakpoint cluster region-abelson (BCR-ABL) and has significant activity in Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). Nilotinib is more potent than imatinib mesylate and is active in cases with imatinib-resistant BCR-ABL mutations.</p>
<p>Bone marrow toxicity associated with the TKIs affects all three cell lineages but is usually dose-dependent and reversible with dose reduction or cessation of treatment. There are a few reports of imatinib-associated bone marrow aplasia,<sup><xref ref-type="bibr" rid="bibr1-1078155212438112">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr5-1078155212438112">5</xref></sup> but only one previously reported case of bone marrow aplasia associated with nilotinib.<sup><xref ref-type="bibr" rid="bibr6-1078155212438112">6</xref></sup> Herein, we report a case of a patient who developed severe bone marrow aplasia secondary to nilotinib.</p>
</sec>
<sec id="sec2-1078155212438112" sec-type="cases"><title>Case report</title>
<p>A 49-year-old man presented with abdominal pain in the spring of 2008. A complete blood count showed a white blood cell count of 130 × 10<sup>9</sup>/L, hemoglobin of 10.4 g/dL and platelet count of 781 × 10<sup>9</sup>/L. Bone marrow aspiration and biopsy revealed 95% cellularity and morphologic findings consistent with CML. Cytogenetic analysis confirmed the presence of the Philadelphia chromosome. Imatinib mesylate was started at a dose of 400 mg/day, and his complete blood count normalized in a few weeks’ time. However, he developed significant nausea, vomiting and myalgias. A bone marrow aspiration and biopsy obtained 7 months later showed 50% cellularity with persistent involvement by CML with positive t[9;22] chromosomal translocation detected by cytogenetics. He was then switched to dasatinib 100 mg/day, but he had an anaphylactic reaction. Therefore, he was then started on nilotinib 400 mg twice a day, which was later changed to 400 mg/day due to severe cytopenias. He had a bone marrow aspiration and biopsy 6 months later, which showed 25% cellularity with 8% blasts consistent with progression. Therefore, nilotinib was increased to 400 mg twice a day. Six months later, another bone marrow aspiration and biopsy showed only 5%–10% cellularity and a complete cytogenetic response. His cytopenias got worse and his bone marrow aspiration and biopsy obtained 7 months later showed only 5% cellularity (<xref ref-type="fig" rid="fig1-1078155212438112">Figure 1</xref>). At that time, he was in complete cytogenetic remission so nilotinib was discontinued. His cytopenias improved and a repeat bone marrow aspiration and biopsy showed improved cellularity (40%) (<xref ref-type="fig" rid="fig2-1078155212438112">Figure 2</xref>) 2 months after discontinuing nilotinib. However, his bone marrow showed the presence of Ph<sup>+</sup> in 13 of 20 metaphases. He was then started on imatinib 400 mg daily, but it was soon discontinued due to severe nausea, vomiting and elevated liver enzymes. The patient was restarted on 200 mg daily of nilotinib, but it was stopped again due to worsening cytopenias and increased liver enzymes. A repeat bone marrow aspiration and biopsy obtained 1 month later showed less than 5% cellularity (<xref ref-type="fig" rid="fig3-1078155212438112">Figure 3</xref>), with the presence of Philadelphia chromosome in 12 of 20 metaphases. He is currently off all therapy and his blood counts have again recovered. Summary of patient’s peripheral blood counts in relation to bone marrow cellularity is outlined in <xref ref-type="table" rid="table1-1078155212438112">Table 1</xref>.
<fig id="fig1-1078155212438112" position="float"><label>Figure 1.</label><caption><p>Bone marrow biopsy shows an aplastic marrow after administration of nilotinib.</p></caption><graphic xlink:href="10.1177_1078155212438112-fig1.tif"/>
</fig>
<fig id="fig2-1078155212438112" position="float"><label>Figure 2.</label><caption><p>Repeated bone marrow biopsy after discontinuation of nilotinib shows a cellularity of 40% with myeloid hypoplasia and islands of erythroid regeneration.</p></caption><graphic xlink:href="10.1177_1078155212438112-fig2.tif"/>
</fig>
<fig id="fig3-1078155212438112" position="float"><label>Figure 3.</label><caption><p>Bone marrow biopsy after reintroduction of nilotinib into therapy demonstrates aplasia.</p></caption><graphic xlink:href="10.1177_1078155212438112-fig3.tif"/>
</fig>
<table-wrap id="table1-1078155212438112" position="float"><label>Table 1.</label><caption><p>Summary of patient’s peripheral blood counts in relation to bone marrow cellularity.</p></caption>
<graphic alternate-form-of="table1-1078155212438112" xlink:href="10.1177_1078155212438112-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Therapy</th>
<th>Bone marrow cellularity (%)</th>
<th>White cell count 10<sup>9</sup>/L</th>
<th>Hemoglobin g/dL</th>
<th>Platelets 10<sup>9</sup>/L</th>
</tr></thead>
<tbody align="left">
<tr>
<td>On imatinib</td>
<td>50</td>
<td>3.6</td>
<td>13.3</td>
<td>323</td>
</tr>
<tr>
<td>On nilotinib low dose</td>
<td>25</td>
<td>5.3</td>
<td>11.9</td>
<td>586</td>
</tr>
<tr>
<td>On nilotinib</td>
<td>5–10</td>
<td>2.5</td>
<td>9.7</td>
<td>42</td>
</tr>
<tr>
<td>On nilotinib</td>
<td>5</td>
<td>2.4</td>
<td>9.8</td>
<td>16</td>
</tr>
<tr>
<td>Off nilotinib</td>
<td>40</td>
<td>1.8</td>
<td>9.6</td>
<td>150</td>
</tr>
<tr>
<td>Restarted on nilotinib</td>
<td>&lt;5</td>
<td>1.3</td>
<td>11.2</td>
<td>30</td>
</tr>
</tbody>
</table>
</table-wrap></p>
</sec>
<sec id="sec3-1078155212438112" sec-type="discussion"><title>Discussion</title>
<p>TKIs have a broad spectrum of hematologic toxicities; however, the possible mechanisms are not well defined. Imatinib is the first introduced TKI, and there are long-term data on its hematologic toxicities. However, the limited experience with second-generation TKIs, dasatinib and nilotinib, does not provide estimates of their long-term toxicities. In the original International Randomized Study of Interferon and STI571 (IRIS) study, grade 3 or 4 neutropenia, thrombocytopenia and anemia were observed in 35%, 20% and 7%, respectively, of patients pretreated with interferon who also received imatinib.<sup><xref ref-type="bibr" rid="bibr7-1078155212438112">7</xref></sup> In the same study, grade 3 or 4 neutropenia, thrombocytopenia and anemia were also seen in 14%, 8% and 3%, respectively, of previously- untreated patients who received imatinib.<sup><xref ref-type="bibr" rid="bibr8-1078155212438112">8</xref></sup> A decrease in bone marrow cellularity to ≤50% was reported in 77% of the 41 CML patients who received imatinib for a median of 13 weeks, and 7 patients developed severe bone marrow hypoplasia with &lt;5% cellularity.<sup><xref ref-type="bibr" rid="bibr9-1078155212438112">9</xref></sup> An 800 mg dose of imatinib is associated with grade 3 or 4 neutropenia in about one third of previously untreated CML patients.<sup><xref ref-type="bibr" rid="bibr10-1078155212438112">10</xref></sup> Dasatinib is a second-generation TKI with potent activity against BCR-ABL, which is also associated with hematologic toxicity and cytopenias. Grade 3 or 4 neutropenia was seen in 45%–52% of CML patients in chronic phase treated with dasatinib.<sup><xref ref-type="bibr" rid="bibr11-1078155212438112">11</xref>,<xref ref-type="bibr" rid="bibr12-1078155212438112">12</xref></sup> Grade 3 or 4 thrombocytopenia was observed in 35% of CML patients treated with dasatinib and grade 3 or 4 anemia was reported in 17%.<sup><xref ref-type="bibr" rid="bibr11-1078155212438112">11</xref>,</sup><sup><xref ref-type="bibr" rid="bibr12-1078155212438112">12</xref></sup> Nilotinib is another potent second-generation TKI and has been associated with grade 3 or 4 neutropenia and thrombocytopenia in 29% of CML patients.<sup><xref ref-type="bibr" rid="bibr13-1078155212438112">13</xref></sup> In another report on nilotinib, grade 3 or 4 neutropenia, thrombocytopenia and anemia were observed in 12%, 11% and 5%, respectively, of CML patients.<sup><xref ref-type="bibr" rid="bibr14-1078155212438112">14</xref></sup> Myelosuppression usually occurs early in the course of treatment with nilotinib.<sup><xref ref-type="bibr" rid="bibr13-1078155212438112">13</xref>,<xref ref-type="bibr" rid="bibr14-1078155212438112">14</xref></sup></p>
<p>The pathobiology of bone marrow suppression associated with TKIs is unclear. There is a possibility that normal hematopoiesis is suppressed by the presence of Ph+ hematopoietic clone and response to TKIs resulting in a reduction in the size of the malignant clone and its myelosuppressive effects. This hypothesis is supported by the observation that the incidence of new-onset grade 3 to 4 cytopenias decreases significantly after 2 years of treatment with imatinib.<sup><xref ref-type="bibr" rid="bibr15-1078155212438112">15</xref></sup> However, this concept would only explain the early hematologic toxicity seen with TKIs. Patients with gastrointestinal stromal tumors who receive imatinib also develop grade 3 or 4 neutropenia, anemia and thrombocytopenia in 5%–8%, 2%–5% and 1%, respectively, of patients.<sup><xref ref-type="bibr" rid="bibr16-1078155212438112">16</xref>,<xref ref-type="bibr" rid="bibr17-1078155212438112">17</xref></sup> Imatinib blocks phosphorylation of tyrosine residues by occupying the ATP-binding site of the ABL tyrosine kinase, c-Abl, PDGF-R and receptor for human stem cell factor c-Kit.<sup><xref ref-type="bibr" rid="bibr18-1078155212438112">18</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr22-1078155212438112">22</xref></sup> Dasatinib binds to and inhibits the growth-promoting activities of SRC, PDGFR and c-Kit and BCR-ABL receptor kinases.<sup><xref ref-type="bibr" rid="bibr23-1078155212438112">23</xref></sup> Nilotinib inhibits BCR-ABL, C-Kit and PDGFR tyrosine kinase.<sup><xref ref-type="bibr" rid="bibr24-1078155212438112">24</xref></sup> Several observations suggest that c-Abl tyrosine kinase has a complex and multifaceted biologic function and is probably involved in normal cell functions such as cell-cycle control, cell death, differentiation, adhesion and mobility.<sup><xref ref-type="bibr" rid="bibr25-1078155212438112">25</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr27-1078155212438112">27</xref></sup> It has been shown that inhibition of c-Abl by using oligodeoxynucleotide antisense results in arrest of CD34+ cells in G0/G1 and blocks CFU-GM formation without induction of apoptosis.<sup><xref ref-type="bibr" rid="bibr28-1078155212438112">28</xref></sup> There is in vitro evidence that c-Kit has a significant role in the normal hematopoiesis,<sup><xref ref-type="bibr" rid="bibr29-1078155212438112">29</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr31-1078155212438112">31</xref></sup> and PDGF is also involved in normal hematopoiesis.<sup><xref ref-type="bibr" rid="bibr32-1078155212438112">32</xref></sup> There is also in vitro evidence that imatinib has growth inhibitory potential and can affect normal hematopoiesis and inhibit normal CD34+ progenitor cells.<sup><xref ref-type="bibr" rid="bibr33-1078155212438112">33</xref></sup><sup>,<xref ref-type="bibr" rid="bibr34-1078155212438112">34</xref></sup> These observations suggest a significant inhibitory effect of TKIs on normal hematopoiesis, which could provide an explanation for the hematologic toxicity associated with this class of medications. Taken together, our case report shows that bone marrow aplasia can be a serious adverse effect of nilotinib, but more clinical data are needed before a definitive association can be established. Therefore, CML patients on TKI therapy need close monitoring.</p>
</sec>
</body>
<back>
<sec id="sec4-1078155212438112"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec5-1078155212438112"><title>Conflict of interest statement</title>
<p>The authors have no conflicts of interest to disclose.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1078155212438112"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lokeshwar</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>L</given-names></name><name><surname>Kumari</surname><given-names>M</given-names></name></person-group>. <article-title>Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia</article-title>. <source>Leuk Lymphoma</source> <year>2005</year>; <volume>46</volume>(<issue>5</issue>): <fpage>781</fpage>–<lpage>784</lpage>.</citation></ref>
<ref id="bibr2-1078155212438112"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chng</surname><given-names>WJ</given-names></name><name><surname>Tan</surname><given-names>LH</given-names></name></person-group>. <article-title>Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia</article-title>. <source>Leuk Res</source> <year>2005</year>; <volume>29</volume>(<issue>6</issue>): <fpage>719</fpage>–<lpage>720</lpage>.</citation></ref>
<ref id="bibr3-1078155212438112"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sumi</surname><given-names>M</given-names></name><name><surname>Tauchi</surname><given-names>T</given-names></name><name><surname>Shimamoto</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy</article-title>. <source>Rinsho Ketsueki</source> <year>2002</year>; <volume>43</volume>(<issue>9</issue>): <fpage>868</fpage>–<lpage>870</lpage>.</citation></ref>
<ref id="bibr4-1078155212438112"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Srinivas</surname><given-names>U</given-names></name><name><surname>Pillai</surname><given-names>LS</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Bone marrow aplasia–a rare complication of imatinib therapy in CML patients</article-title>. <source>Am J Hematol</source> <year>2007</year>; <volume>82</volume>(<issue>4</issue>): <fpage>314</fpage>–<lpage>316</lpage>.</citation></ref>
<ref id="bibr5-1078155212438112"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ram</surname><given-names>R</given-names></name><name><surname>Gafter-Gvili</surname><given-names>A</given-names></name><name><surname>Okon</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?</article-title>. <source>Acta Haematol</source> <year>2008</year>; <volume>119</volume>(<issue>2</issue>): <fpage>104</fpage>–<lpage>107</lpage>.</citation></ref>
<ref id="bibr6-1078155212438112"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quintas-Cardama</surname><given-names>A</given-names></name><name><surname>De Souza Santos</surname><given-names>FP</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure</article-title>. <source>Cancer</source> <year>2009</year>; <volume>115</volume>(<issue>17</issue>): <fpage>3935</fpage>–<lpage>3943</lpage>.</citation></ref>
<ref id="bibr7-1078155212438112"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Sawyers</surname><given-names>C</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia</article-title>. <source>N Engl J Med</source> <year>2002</year>; <volume>346</volume>(<issue>9</issue>): <fpage>645</fpage>–<lpage>652</lpage>.</citation></ref>
<ref id="bibr8-1078155212438112"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>SG</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name></person-group>. <article-title>Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia</article-title>. <source>Semin Hematol</source> <year>2003</year>; <volume>40</volume>(<issue>2 Suppl 2</issue>): <fpage>26</fpage>–<lpage>30</lpage>.</citation></ref>
<ref id="bibr9-1078155212438112"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasserjian</surname><given-names>RP</given-names></name><name><surname>Boecklin</surname><given-names>F</given-names></name><name><surname>Parker</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response</article-title>. <source>Am J Clin Pathol</source> <year>2002</year>; <volume>117</volume>(<issue>3</issue>): <fpage>360</fpage>–<lpage>367</lpage>.</citation></ref>
<ref id="bibr10-1078155212438112"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph + CML-CP)</article-title>. <source>Proc Am Soc Clin Oncol</source> <year>2002</year>; <volume>21</volume><comment>: abstract 1043</comment></citation></ref>
<ref id="bibr11-1078155212438112"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Talpaz</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>NP</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias</article-title>. <source>N Engl J Med</source> <year>2006</year>; <volume>354</volume>(<issue>24</issue>): <fpage>2531</fpage>–<lpage>2541</lpage>.</citation></ref>
<ref id="bibr12-1078155212438112"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>MK</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Seol</surname><given-names>YM</given-names></name><etal/></person-group>. <article-title>Nilotinib-induced bone marrow aplasia</article-title>. <source>Eur J Haematol</source> <year>2009</year>; <volume>83</volume>(<issue>2</issue>): <fpage>161</fpage>–<lpage>162</lpage>.</citation></ref>
<ref id="bibr13-1078155212438112"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Giles</surname><given-names>F</given-names></name><name><surname>Gattermann</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance</article-title>. <source>Blood</source> <year>2007</year>; <volume>110</volume>(<issue>10</issue>): <fpage>3540</fpage>–<lpage>3546</lpage>.</citation></ref>
<ref id="bibr14-1078155212438112"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase</article-title>. <source>J Clin Oncol</source> <year>2010</year>; <volume>28</volume>(<issue>3</issue>): <fpage>392</fpage>–<lpage>397</lpage>.</citation></ref>
<ref id="bibr15-1078155212438112"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>O'Brien</surname><given-names>SG</given-names></name><etal/></person-group>. <article-title>Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</article-title>. <source>N Engl J Med</source> <year>2006</year>; <volume>355</volume>(<issue>23</issue>): <fpage>2408</fpage>–<lpage>2417</lpage>.</citation></ref>
<ref id="bibr16-1078155212438112"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demetri</surname><given-names>GD</given-names></name><name><surname>von Mehren</surname><given-names>M</given-names></name><name><surname>Blanke</surname><given-names>CD</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</article-title>. <source>N Engl J Med</source> <year>2002</year>; <volume>347</volume>(<issue>7</issue>): <fpage>472</fpage>–<lpage>480</lpage>.</citation></ref>
<ref id="bibr17-1078155212438112"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dagher</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors</article-title>. <source>Clin Cancer Res</source> <year>2002</year>; <volume>8</volume>(<issue>10</issue>): <fpage>3034</fpage>–<lpage>3038</lpage>.</citation></ref>
<ref id="bibr18-1078155212438112"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchdunger</surname><given-names>E</given-names></name><name><surname>Zimmermann</surname><given-names>J</given-names></name><name><surname>Mett</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2- phenylaminopyrimidine derivative</article-title>. <source>Cancer Res</source> <year>1996</year>; <volume>56</volume>(<issue>1</issue>): <fpage>100</fpage>–<lpage>104</lpage>.</citation></ref>
<ref id="bibr19-1078155212438112"><label>19</label><citation citation-type="other"><comment>Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. <italic>Nat Med</italic> 1996; 2: 561–566</comment>.</citation></ref>
<ref id="bibr20-1078155212438112"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchdunger</surname><given-names>E</given-names></name><name><surname>Cioffi</surname><given-names>CL</given-names></name><name><surname>Law</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors</article-title>. <source>J Pharmacol Exp Ther</source> <year>2000</year>; <volume>295</volume>(<issue>1</issue>): <fpage>139</fpage>–<lpage>145</lpage>.</citation></ref>
<ref id="bibr21-1078155212438112"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Lydon</surname><given-names>NB</given-names></name></person-group>. <article-title>Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia</article-title>. <source>J Clin Invest</source> <year>2000</year>; <volume>105</volume>(<issue>1</issue>): <fpage>3</fpage>–<lpage>7</lpage>.</citation></ref>
<ref id="bibr22-1078155212438112"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Druker</surname><given-names>BJ</given-names></name></person-group>. <article-title>Imatinib alone and in combination for chronic myeloid leukemia</article-title>. <source>Semin Hematol</source> <year>2003</year>; <volume>40</volume>(<issue>1</issue>): <fpage>50</fpage>–<lpage>58</lpage>.</citation></ref>
<ref id="bibr23-1078155212438112"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puttini</surname><given-names>M</given-names></name><name><surname>Coluccia</surname><given-names>AM</given-names></name><name><surname>Boschelli</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells</article-title>. <source>Cancer Res</source> <year>2006</year>; <volume>66</volume>(<issue>23</issue>): <fpage>11314</fpage>–<lpage>11322</lpage>.</citation></ref>
<ref id="bibr24-1078155212438112"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weisberg</surname><given-names>E</given-names></name><name><surname>Manley</surname><given-names>PW</given-names></name><name><surname>Breitenstein</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</article-title>. <source>Cancer Cell</source> <year>2005</year>; <volume>7</volume>(<issue>2</issue>): <fpage>129</fpage>–<lpage>141</lpage>.</citation></ref>
<ref id="bibr25-1078155212438112"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Etten</surname><given-names>RA</given-names></name></person-group>. <article-title>Cycling, stressed-out and nervous: cellular functions of c-Abl</article-title>. <source>Trends Cell Biol</source> <year>1999</year>; <volume>9</volume>(<issue>5</issue>): <fpage>179</fpage>–<lpage>186</lpage>.</citation></ref>
<ref id="bibr26-1078155212438112"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JY</given-names></name></person-group>. <article-title>Regulation of cell death by the Abl tyrosine kinase</article-title>. <source>Oncogene</source> <year>2000</year>; <volume>19</volume>(<issue>49</issue>): <fpage>5643</fpage>–<lpage>5650</lpage>.</citation></ref>
<ref id="bibr27-1078155212438112"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JM</given-names></name><name><surname>Baskaran</surname><given-names>R</given-names></name><name><surname>Taagepera</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1996</year>; <volume>93</volume>(<issue>26</issue>): <fpage>15174</fpage>–<lpage>15179</lpage>.</citation></ref>
<ref id="bibr28-1078155212438112"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosti</surname><given-names>V</given-names></name><name><surname>Bergamaschi</surname><given-names>G</given-names></name><name><surname>Lucotti</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors</article-title>. <source>Blood</source> <year>1995</year>; <volume>86</volume>(<issue>9</issue>): <fpage>3387</fpage>–<lpage>3393</lpage>.</citation></ref>
<ref id="bibr29-1078155212438112"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petzer</surname><given-names>AL</given-names></name><name><surname>Eaves</surname><given-names>CJ</given-names></name><name><surname>Barnett</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia</article-title>. <source>Blood</source> <year>1997</year>; <volume>90</volume>(<issue>1</issue>): <fpage>64</fpage>–<lpage>69</lpage>.</citation></ref>
<ref id="bibr30-1078155212438112"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brummendorf</surname><given-names>TH</given-names></name><name><surname>Dragowska</surname><given-names>W</given-names></name><name><surname>Zijlmans</surname><given-names>JMJM</given-names></name><etal/></person-group>. <article-title>Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells</article-title>. <source>J Exp Med</source> <year>1998</year>; <volume>188</volume>(<issue>6</issue>): <fpage>1117</fpage>–<lpage>1124</lpage>.</citation></ref>
<ref id="bibr31-1078155212438112"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glimm</surname><given-names>H</given-names></name><name><surname>Eaves</surname><given-names>CJ</given-names></name></person-group>. <article-title>Direct evidence for multiple self-renewal divisions of human in vivo repopulating hematopoietic cells in short-term culture</article-title>. <source>Blood</source> <year>1999</year>; <volume>94</volume>(<issue>7</issue>): <fpage>2161</fpage>–<lpage>2168</lpage>.</citation></ref>
<ref id="bibr32-1078155212438112"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>RJ</given-names></name><name><surname>Zhang</surname><given-names>XB</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Platelet-derived growth factor promotes ex vivo expansion of CD34+ cells from human cord blood and enhances long- term culture-initiating cells, non-obese diabetic/severe combined immunodeficient repopulating cells and formation of adherent cells</article-title>. <source>Br J Haematol</source> <year>2002</year>; <volume>117</volume>(<issue>3</issue>): <fpage>735</fpage>–<lpage>746</lpage>.</citation></ref>
<ref id="bibr33-1078155212438112"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartolovic</surname><given-names>K</given-names></name><name><surname>Balabanov</surname><given-names>S</given-names></name><name><surname>Hartmann</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Inhibitory effect of imatinib on normal progenitor cells in vitro</article-title>. <source>Blood</source> <year>2004</year>; <volume>103</volume>(<issue>2</issue>): <fpage>523</fpage>–<lpage>529</lpage>.</citation></ref>
<ref id="bibr34-1078155212438112"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>SM</given-names></name><name><surname>Jorgensen</surname><given-names>HG</given-names></name><name><surname>Allan</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro</article-title>. <source>Blood</source> <year>2002</year>; <volume>99</volume>(<issue>1</issue>): <fpage>319</fpage>–<lpage>325</lpage>.</citation></ref>
</ref-list>
</back>
</article>